Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through 
inhibition of the protein kinase C signaling pathway

Xie,Xin; Wu,Meng‑Yao; Shou,Liu‑Mei; Chen,Long‑Pei; Gong,Fei‑Ran; Chen,Kai; Li,Dao‑Ming; Duan,Wei‑Ming; Xie,Yu‑Feng; Mao,Yi‑Xiang; Li,Wei; Tao,Min

doi:10.3892/ol.2014.2711

Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway

Authors:
- Xin Xie
- Meng‑Yao Wu
- Liu‑Mei Shou
- Long‑Pei Chen
- Fei‑Ran Gong
- Kai Chen
- Dao‑Ming Li
- Wei‑Ming Duan
- Yu‑Feng Xie
- Yi‑Xiang Mao
- Wei Li
- Min Tao
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: November 19, 2014 https://doi.org/10.3892/ol.2014.2711
Pages: 837-844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cantharidin is an active constituent of mylabris, a traditional Chinese therapeutic agent. Cantharidin is a potent and selective inhibitor of protein phosphatase 2A (PP2A). Cantharidin has been previously reported to efficiently repress the growth of pancreatic cancer cells. However, excessively activated protein kinase C (PKC) has been shown to improve cell survival following the adminstration of cantharidin. Tamoxifen is widely used in the treatment of estrogen receptor‑positive breast cancer. In addition, an increasing number of studies have found that tamoxifen selectively inhibits PKC and represses growth in estrogen receptor‑negative cancer cells. Administration of a combination of PKC inhibitor and PP2A inhibitors has been demonstrated to exert a synergistic anticancer effect. The proliferation of pancreatic cancer cells was analyzed by 3-(4,5-dimethyltiazol-2-yl]2, 5-diphenyltetrazo-lium bromide assay. The expression levels of ERα and ERβ in various pancreatic cancer cell lines were determined by reverse transcription polymerase chain reaction. In addition, the protein levels of PKCα and phosphorylated PKCα in pancreatic cell lines were analyzed by western blot analysis. In the present study, tamoxifen was found to exert a cytotoxic effect against pancreatic cancer cells independent of the hormone receptor status. Tamoxifen repressed the phosphorylation of PKC, and amplified the anticancer effect induced by cantharidin and norcantharidin. The findings reveal a novel potential strategy against pancreatic cancer using co‑treatment with tamoxifen plus cantharidin or cantharidin derivatives.

View Figures

View References

1	Wolfgang CL, Herman JM, Laheru DA, et al: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
2	Paulson AS, Tran Cao HS, Tempero MA and Lowy AM: Therapeutic advances in pancreatic cancer. Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
3	Peng F, Wei YQ, Tian L, et al: Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol. 128:223–230. 2002. View Article : Google Scholar : PubMed/NCBI
4	Chen YN, Chen JC, Yin SC, et al: Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer. 100:158–165. 2002. View Article : Google Scholar : PubMed/NCBI
5	Huan SK, Lee HH, Liu DZ, Wu CC and Wang CC: Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. Toxicology. 223:136–143. 2006. View Article : Google Scholar : PubMed/NCBI
6	Li W, Xie L, Chen Z, et al: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li W, Chen Z, Zong Y, et al: PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKalpha and sustained activation of the NF-kappaB pathway. Cancer Lett. 304:117–127. 2011. View Article : Google Scholar : PubMed/NCBI
8	Li W, Chen Z, Gong FR, et al: Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. Eur J Cancer. 47:2654–2664. 2011. View Article : Google Scholar : PubMed/NCBI
9	Li W, Li DM, Chen K, et al: Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the alpha-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study. BMC Cancer. 12:5472012. View Article : Google Scholar
10	Millward TA, Zolnierowicz S and Hemmings BA: Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci. 24:186–191. 1999. View Article : Google Scholar : PubMed/NCBI
11	Janssens V, Goris J and Van Hoof C: PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 15:34–41. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chen YJ, Kuo CD, Tsai YM, et al: Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs. 19:55–64. 2008. View Article : Google Scholar
13	Schweyer S, Bachem A, Bremmer F, et al: Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J Pathol. 213:72–81. 2007. View Article : Google Scholar : PubMed/NCBI
14	Tanaka T, Masuda H, Naito M and Tamai H: Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Anticancer Res. 21:2463–2469. 2001.PubMed/NCBI
15	McClay EF, McClay MT, Monroe L, Jones JA and Winski PJ: A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res. 11:309–313. 2001. View Article : Google Scholar : PubMed/NCBI
16	Sudo K, Monsma FJ Jr and Katzenellenbogen BS: Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology. 112:425–434. 1983. View Article : Google Scholar : PubMed/NCBI
17	Lam HY: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 118:27–32. 1984. View Article : Google Scholar : PubMed/NCBI
18	O’Brian CA, Liskamp RM, Solomon DH and Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res. 45:2462–2465. 1985.PubMed/NCBI
19	Su HD, Mazzei GJ, Vogler WR and Kuo JF: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol. 34:3649–3653. 1985. View Article : Google Scholar : PubMed/NCBI
20	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
21	Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
22	Andrén-Sandberg A, Hoem D and Bäckman PL: Other risk factors for pancreatic cancer: hormonal aspects. Ann Oncol. 10(Suppl 4): 131–135. 1999. View Article : Google Scholar : PubMed/NCBI
23	Jordan VC and Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev. 20:253–278. 1999.PubMed/NCBI
24	Tomao S, Romiti A, Massidda B, et al: A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res. 22:2361–2364. 2002.PubMed/NCBI
25	Eckel F, Lersch C, Lippl F, Assmann G and Schulte-Frohlinde E: Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. J Exp Clin Cancer Res. 19:295–300. 2000.
26	Efferth T, Fu YJ, Zu YG, et al: Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem. 14:2024–2032. 2007. View Article : Google Scholar : PubMed/NCBI
27	Chan E, Tan M, Xin J, Sudarsanam S and Johnson DE: Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel. 13:50–65. 2010.PubMed/NCBI
28	Jiang JC: English translation of terms of prescription-monarch, minister, assistant and guide. Zhongguo Zhong Xi Yi Jie He Za Zhi. 30:11052010.(In Chinese).
29	Wang L, Zhou GB, Liu P, et al: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 105:4826–4831. 2008. View Article : Google Scholar : PubMed/NCBI
30	Edmond KM, Kortsalioudaki C, Scott S, et al: Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 379:547–556. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wu JJ, Ai CZ, Liu Y, et al: Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes. Curr Drug Metab. 13:599–614. 2012. View Article : Google Scholar : PubMed/NCBI
32	Tseng YP, Wu YC, Leu YL, Yeh SF and Chou CK: Scutellariae radix suppresses hepatitis B virus production in human hepatoma cells. Front Biosci (Elite Ed). 2:1538–1547. 2010. View Article : Google Scholar
33	Li HB, Ge YK, Zhang L and Zheng XX: Astragaloside IV improved barrier dysfunction induced by acute high glucose in human umbilical vein endothelial cells. Life Sci. 79:1186–1193. 2006. View Article : Google Scholar : PubMed/NCBI
34	Lan TH, Xu ZW, Wang Z, et al: Ginsenoside Rb1 prevents homocysteine-induced endothelial dysfunction via PI3K/Akt activation and PKC inhibition. Biochem Pharmacol. 82:148–155. 2011. View Article : Google Scholar : PubMed/NCBI
35	Zong Y, Ai QL, Zhong LM, et al: Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory responses via the phospholipase C-gamma1 signaling pathway in murine BV-2 microglial cells. Curr Med Chem. 19:770–779. 2012. View Article : Google Scholar
36	He CL, Yi PF, Fan QJ, et al: Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-kappaB signaling pathways in LPS-treated rat cardiac microvascular endothelial cells. Immunopharmacol Immunotoxicol. 35:215–224. 2013. View Article : Google Scholar